“ALS-specific biology and chemistry takes time, but careful preclinical studies are essential for more rational therapeutic candidates.”
A great thought presented by Erin Fleming, Vice President, Research and Development at ProJenX during the Built for Speed: Strategies to Improve Clinical Trial Efficiency session here at #ALSNexus!
Join ALS Canada, on May 2 at 1:00 pm ET, for ALS Clinical Trials Unboxed. This month, Erin Fleming, Vice-President, Research and Development at ProJenX will present on a Phase 1 clinical study to evaluate prosetin for ALS. To register for webinar, visit https://t.co/Vvmue3BQ6h.
Recently, the @US_FDA has lifted its partial clinical hold on @ProJenX’s hybrid phase 1 study assessing its investigational MAP4 kinase (MAP4K) inhibitor prosetin as a potential treatment for patients with #ALS. @Columbia@JinsyMd
https://t.co/nODoPwYyUy
@NISHwmn We couldn't agree more. Our decisions are guided by a wonderful community advisory board (more here: https://t.co/bMP7DDZisv) and we welcome additional guidance every step of the way. Please stay in touch!
ProJenX is excited announce the formation of our Scientific Advisory Board. This world-class group of researchers and clinicians will guide our efforts to advance prosetin in ALS and other neurodegenerative diseases. Read more here: https://t.co/rJ6DfqLo4x
We are very excited to announce the authorization of a clinical trial application (CTA) by Health Canada for the first-in-patient study of prosetin, a novel, CNS-penetrant MAP4K inhibitor developed for ALS. Read more: https://t.co/4dZ9WKzmt7
From @AlexWestchester at @GENbio, a feature on the long-term research collaboration that led to our investigational drug prosetin, and our development plans in #ALS. Read more: https://t.co/1dyLgoISNf